Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios*, J. Remon, S. Novello, N. Blais, R. Califano, T. Cufer, A. M. Dingemans, S. V. Liu, N. Peled, N. A. Pennell, M. Reck, C. Rolfo, D. Tan, J. Vansteenkiste, H. West, B. Besse

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1686-1688
Number of pages3
JournalAnnals of Oncology
Volume30
Issue number11
DOIs
Publication statusPublished - Nov 2019

Keywords

  • NIVOLUMAB
  • DOCETAXEL
  • 1ST-LINE

Cite this